Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
Progenity, Inc. (NASDAQ: PROG) will report its first quarter 2021 financial results on May 13, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Progenity, Inc. (NASDAQ: PROG) will report its first quarter 2021 financial results on May 13, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. Progenity specializes in the development and commercialization of molecular testing products aimed at improving patient outcomes through precision medicine. The company uses a multi-omics approach in its testing and investigational device development, focusing on enhancing diagnostics and targeted therapies.
Positive
- Established track record in developing and commercializing molecular testing products.
- Focus on precision medicine with a multi-omics approach.
Negative
- None.
Details
News Market Reaction – PROG
The recorded move for PROG in the trading session of this news was -7.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 6146238. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.progenity.com.
About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.